Joint injection shows promise for stopping repeat bleeds in hemophilia
NCT ID NCT07187661
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether injecting bevacizumab (a drug that blocks blood vessel growth) into the joints of people with hemophilia can prevent repeated bleeding episodes. Eighteen participants with chronic synovitis (joint inflammation) received the injection. Researchers measured changes in bleeding rates, joint health, and MRI scans over three months to see if the treatment reduced bleeds and improved joint condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bevacizumab (Avastin), a drug that blocks blood vessel growth
What this could lead to
If it works, this could offer a new way to reduce painful joint bleeds and improve joint health in people with hemophilia.
What could go wrong
This is a very small, early study with only 18 people and no comparison group. The effects may not be confirmed in larger trials, and there is a risk of side effects from the injection or the drug itself.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hayatabad Medical Complex
Peshawar, KPK, 25000, Pakistan
-
Institute of Pathology and Diagnostic Medicine (IPDM)
Peshawar, KPK, 25000, Pakistan